Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period

secondary prevention E levated low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk of adverse ischemic outcomes in the early post-acute coronary syndrome (ACS) period. he EVACS trial (Evolocumab in Acute Coronary Syndrome; ClinicalTrials.gov, Unique identifier: NCT035153... View More